表紙
市場調査レポート

出血熱:パイプライン製品の分析

Hemorrhagic Fever - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 257831
出版日 ページ情報 英文 249 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
出血熱:パイプライン製品の分析 Hemorrhagic Fever - Pipeline Review, H2 2014
出版日: 2014年11月30日 ページ情報: 英文 249 Pages
概要

出血熱はウィルスが原因の重症疾患です。この感染症は血液が凝固する能力を阻害し、小さな血管の壁を傷つけ、血液を漏れやすくします。症状には発熱、めまい、疲労感、衰弱、ショック状態、昏睡状態、腎機能障害、および肝機能障害などがあります。治療には抗ウィルス薬が用いられます。

当レポートでは、出血熱に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

出血熱の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

開発中の治療薬:大学/機関別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/機関別

治療薬の開発に従事している企業

  • Peregrine Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • SIGA Technologies, Inc.
  • Evolva SA.
  • Integrated BioTherapeutics, Inc.
  • Hawaii Biotech, Inc.
  • Navigen Pharmaceuticals, Inc

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 腎症候群を伴う出血熱向けワクチン
  • DNAワクチン
  • EV-075
  • bavituximab
  • パンフィロウイルスVLPwakutinn
  • EMER-FABプロジェクト
  • ダニ媒介性フラビウイルスワクチン
  • BCX-4430
  • ST-161
  • Slit2N

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5781IDB

Summary

Global Markets Direct's, 'Hemorrhagic Fever - Pipeline Review, H2 2014', provides an overview of the Hemorrhagic Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Fever
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hemorrhagic Fever and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Fever
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemorrhagic Fever Overview
  • Therapeutics Development
    • Pipeline Products for Hemorrhagic Fever - Overview
    • Pipeline Products for Hemorrhagic Fever - Comparative Analysis
  • Hemorrhagic Fever - Therapeutics under Development by Companies
  • Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes
  • Hemorrhagic Fever - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hemorrhagic Fever - Products under Development by Companies
  • Hemorrhagic Fever - Products under Investigation by Universities/Institutes
  • Hemorrhagic Fever - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • AlphaVax, Inc.
    • Arbovax, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • Chimerix, Inc.
    • Crucell N.V.
    • Epirus Biopharmaceuticals, Inc.
    • Evolva SA
    • FIT Biotech Oyj
    • GeoVax Labs, Inc.
    • GlaxoSmithKline plc
    • Hawaii Biotech, Inc.
    • Hemispherx Biopharma, Inc.
    • Humabs BioMed SA
    • iBio, Inc.
    • Immunovaccine, Inc.
    • Inovio Pharmaceuticals, Inc.
    • Integrated BioTherapeutics, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Medicago Inc.
    • Microbiotix, Inc.
    • Myelo Therapeutics GmbH
    • NanoViricides, Inc.
    • Navigen Pharmaceuticals, Inc.
    • NewLink Genetics Corporation
    • Novavax, Inc.
    • Panacea Biotec Limited
    • Peregrine Pharmaceuticals, Inc.
    • Profectus BioSciences, Inc.
    • Sarepta Therapeutics, Inc.
    • SIGA Technologies, Inc.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • SKAU Vaccines ApS
    • Summit Corporation plc
    • Tekmira Pharmaceuticals Corp.
    • Themis Bioscience GmbH
    • Toyama Chemical Co., Ltd.
    • Vaxart, Inc.
  • Hemorrhagic Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 1-E703 - Drug Profile
    • ADS-324 - Drug Profile
    • ANSX-109 - Drug Profile
    • ANSX-142 - Drug Profile
    • Antibodies for Crimean Congo Hemorrhagic Fever - Drug Profile
    • ARD-5 - Drug Profile
    • AVI-7012 - Drug Profile
    • AVI-7288 - Drug Profile
    • bavituximab - Drug Profile
    • BCX-4430 - Drug Profile
    • BG-323 - Drug Profile
    • BPSC-1001 - Drug Profile
    • brincidofovir - Drug Profile
    • crimean-congo hemorrhagic fever vaccine - Drug Profile
    • DEF-201 - Drug Profile
    • dengue virus vaccine (tetravalent) - Drug Profile
    • DengueCide - Drug Profile
    • DiTU - Drug Profile
    • DNA Vaccines - Drug Profile
    • Drugs for Ebola and Marburg Infections - Drug Profile
    • ebola (virus like particles) vaccine - Drug Profile
    • ebola and marburg vaccine (trivalent) - Drug Profile
    • Ebola Vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • Ebola Vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine - Drug Profile
    • ebola vaccine + marburg vaccine - Drug Profile
    • ebola vaccine [zaire] - Drug Profile
    • ebola virus vaccine - Drug Profile
    • EMER-IT - Drug Profile
    • ET-007 - Drug Profile
    • ETX-101 - Drug Profile
    • EV-075 - Drug Profile
    • favipiravir - Drug Profile
    • Filovirus Vaccine - Drug Profile
    • GOVXE-301 - Drug Profile
    • GOVXE-302 - Drug Profile
    • GreEMTri - Drug Profile
    • hemorrhagic fever (bivalent) vaccine - Drug Profile
    • imatinib mesylate - Drug Profile
    • INO-4200 - Drug Profile
    • interferon alfa-n3 - Drug Profile
    • JK-05 - Drug Profile
    • lassa fever vaccine - Drug Profile
    • lassa fever vaccine 1 - Drug Profile
    • lassa fever vaccine 2 - Drug Profile
    • LCTA-949 - Drug Profile
    • marburg vaccine - Drug Profile
    • marburg vaccine - Drug Profile
    • marburg virus vaccine - Drug Profile
    • MMCatLMC - Drug Profile
    • Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
    • Monoclonal Antibodies for Rift Valley Fever - Drug Profile
    • Monoclonal Antibodies for Viral Infections - Drug Profile
    • Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Drug Profile
    • Monoclonal Antibody for Ebola Virus Infections - Drug Profile
    • Monoclonal Antibody for Marburg Virus - Drug Profile
    • MVA-BN-Filoviruses Vaccine - Drug Profile
    • Myelo-001 - Drug Profile
    • NoBola - Drug Profile
    • oxocarbazate - Drug Profile
    • panfilovirus (multivalent) vaccine - Drug Profile
    • rintatolimod - Drug Profile
    • Slit2N - Drug Profile
    • Small Molecule for Argentine Hemorrhagic Fever - Drug Profile
    • Small Molecule for Bunya Virus - Drug Profile
    • Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection - Drug Profile
    • Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections - Drug Profile
    • Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
    • Small Molecules to Inhibit SAH Hydrolase for Ebola Virus Infection - Drug Profile
    • Small Molecules to Target Estrogen Receptor for Ebola Virus Infection - Drug Profile
    • SMT-15000 - Drug Profile
    • ST-161 - Drug Profile
    • ST-193 - Drug Profile
    • Synthetic Peptides for Ebola Virus - Drug Profile
    • thiocarbazate - Drug Profile
    • TKM-100701 - Drug Profile
    • TKM-100802 - Drug Profile
    • TKM-Marburg - Drug Profile
    • TSI-GSD-200 - Drug Profile
    • yellow fever and arenavirus vaccine - Drug Profile
    • yellow fever vaccine - Drug Profile
    • yellow fever vaccine - Drug Profile
    • yellow fever vaccine - Drug Profile
    • yellow fever vaccine - Drug Profile
    • yellow fever vaccine - Drug Profile
    • yellow fever vaccine - Drug Profile
    • yellow fever vaccine (YF17D) - Drug Profile
    • ZMAb - Drug Profile
    • ZMapp - Drug Profile
  • Hemorrhagic Fever - Recent Pipeline Updates
  • Hemorrhagic Fever - Dormant Projects
  • Hemorrhagic Fever - Discontinued Products
  • Hemorrhagic Fever - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemorrhagic Fever, H2 2014
  • Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Development by Companies, H2 2014 (Contd..1)
  • Number of Products under Development by Companies, H2 2014 (Contd..2)
  • Number of Products under Development by Companies, H2 2014 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Comparative Analysis by Unknown Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Development by Companies, H2 2014 (Contd..1)
  • Products under Development by Companies, H2 2014 (Contd..2)
  • Products under Development by Companies, H2 2014 (Contd..3)
  • Products under Development by Companies, H2 2014 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2014
  • Hemorrhagic Fever - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by AlphaVax, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Arbovax, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Chimerix, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Crucell N.V., H2 2014
  • Hemorrhagic Fever - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Evolva SA, H2 2014
  • Hemorrhagic Fever - Pipeline by FIT Biotech Oyj, H2 2014
  • Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by GlaxoSmithKline plc, H2 2014
  • Hemorrhagic Fever - Pipeline by Hawaii Biotech, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Hemispherx Biopharma, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Humabs BioMed SA, H2 2014
  • Hemorrhagic Fever - Pipeline by iBio, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Janssen Pharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Medicago Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Microbiotix, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Myelo Therapeutics GmbH, H2 2014
  • Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by NewLink Genetics Corporation, H2 2014
  • Hemorrhagic Fever - Pipeline by Novavax, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Panacea Biotec Limited, H2 2014
  • Hemorrhagic Fever - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by SIGA Technologies, Inc., H2 2014
  • Hemorrhagic Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2014
  • Hemorrhagic Fever - Pipeline by SKAU Vaccines ApS, H2 2014
  • Hemorrhagic Fever - Pipeline by Summit Corporation plc, H2 2014
  • Hemorrhagic Fever - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014
  • Hemorrhagic Fever - Pipeline by Themis Bioscience GmbH, H2 2014
  • Hemorrhagic Fever - Pipeline by Toyama Chemical Co., Ltd., H2 2014
  • Hemorrhagic Fever - Pipeline by Vaxart, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H2 2014
  • Hemorrhagic Fever - Dormant Projects, H2 2014
  • Hemorrhagic Fever - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Hemorrhagic Fever, H2 2014
  • Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top